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Abstract
Background Proteinuria has been commonly reported in patients with COVID-19. However, only dipstick tests have been 
frequently used thus far. Here, the quantification and characterization of proteinuria were investigated and their association 
with mortality was assessed.
Methods This retrospective, observational, single center study included 153 patients, hospitalized with COVID-19 between 
March 28th and April 30th, 2020, in whom total proteinuria and urinary α1-microglobulin (a marker of tubular injury) were 
measured. Association with mortality was evaluated, with a follow-up until May 7th, 2020.
Results According to the Kidney Disease Improving Global Outcomes staging, 14% (n = 21) of the patients had category 1 
proteinuria (< 150 mg/g of urine creatinine), 42% (n = 64) had category 2 (between 150 and 500 mg/g) and 44% (n = 68) had 
category 3 proteinuria (over 500 mg/g). Urine α1-microglobulin concentration was higher than 15 mg/g in 89% of patients. 
After a median follow-up of 27 [14;30] days, the mortality rate reached 18%. Total proteinuria and urinary α1-microglobulin 
were associated with mortality in unadjusted and adjusted models. This association was stronger in subgroups of patients 
with normal renal function and without a urinary catheter.
Conclusions Proteinuria is frequent in patients with COVID-19. Its characterization suggests a tubular origin, with increased 
urinary α1-microglobulin. Tubular proteinuria was associated with mortality in COVID-19 in our restropective, observational 
study.
Keywords Proteinuria · COVID-19 · α1-microglobulin · Tubular proteinuria
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Introduction
The SARS-CoV-2 (severe acute respiratory syndrome cor-
onavirus 2) causes “coronavirus disease 2019” (COVID-
19) [1, 2] which is characterized by diffuse alveolar dam-
age leading to an acute respiratory distress syndrome [3]. 
Other organs may also be affected [2–4]. Cheng et al. [2] 
early described a high prevalence of proteinuria (43.9%) 
and hematuria (26.7%) in a cohort of 442 patients in 
Wuhan, China [2]. These data suggest specific kidney 
damage caused by SARS-CoV-2, although it remains 
unclear whether the virus is present in the kidney or urine, 
or not [5, 6]. Since this first publication, measurement of 
proteinuria has been recommended in our institution, using 
quantitative measurements and characterization of pro-
teinuria. Dipstick methods of assessing proteinuria have 
well-established limitations [7]. In the present paper, we 
aimed to characterize the prevalence and type of proteinu-
ria observed in patients with COVID-19, and also to assess 
the prognostic importance of proteinuria in COVID-19.
Patients and methods
This was an observational retrospective single-center 
study. Clinical and biological variables were extracted 
from the computer-based medical records. All data were 
anonymized and the study was approved by the Ethics 
Committee of Liège Academic Hospital.
Inclusion criteria All patients older than 18  years 
admitted to Liège Academic Hospital between March 
28th and April 30th, 2020 with a positive COVID-19 
test were eligible. A positive test was obtained by reverse 
transcriptase polymerase chain reaction (RT-PCR, Cobas 
SARS CoV-2 Test with Cobas 8800) via nasal swab or 
antigen testing. Only one patient had positive antigen 
without RT-PCR. Only patients with at least one complete 
urine analysis (red blood cell (RBC) count, total proteinu-
ria and α1-microglobulin) were considered for the present 
analysis. Quantification of urinary β2-microglobulin was 
also available in a subset of patients. Patients on renal 
replacement therapy (i.e. renal transplantation or chronic 
dialysis) were excluded.
Urine samples The day the urine was collected was 
considered Day 0 (D0). A second urine analysis was per-
formed in some patients on Day 7 (D7). Total proteinuria 
(expressed in mg/g of urine creatinine) was measured on a 
random spot urine sample, with Abbott Alinity instrument, 
whereas urine α1-microglobulin and β2-microglobulin were 
determined with the Siemens Dimension Vista instrument. 
Proteinuria was staged according to the KDIGO (Kidney 
Disease Improving Global Outcomes) categorization sys-
tem [8]: normal or category 1 (< 150 mg/g), category 2 
(between 150 and 500 mg/g), category 3 (over 500 mg/g). 
Urine α1-microglobulin was expressed in mg/g of urine 
creatinine. Tertiles and a fixed threshold were considered 
(> 15 mg/g based on the current literature [9, 10]). Urine 
β2-microglobulin was expressed in mg/L. Tertiles and a 
result above 0.19 mg/L was considered abnormal [11]. The 
number of RBCs in the urine was automatically evaluated 
by the Sedimax automate (positive if > 10 RBC per field). 
Because proteinuria and hematuria can be impacted by uri-
nary catheter (UC), analyses were repeated in subgroups 
without UC at D0.
Clinical, biological and radiological parameters
The following variables were considered: age, weight, 
height, body mass index (BMI), history of hypertension 
(based on medical records and/or the presence of antihy-
pertensive medications at admission), history of diabetes 
(based on medical records and/or the presence of specific 
therapy at admission), active cancer, active smoking, and 
history of chronic kidney disease (CKD) (based on medical 
records, not on biological data). Biological data of interest 
were considered at the closest time of measurement to D0 
within a maximum of 48 h. All biological data were gener-
ated from one single laboratory (Unilab, CHU de Liège) 
accredited for ISO 15,189 Guideline. The following varia-
bles were collected: C-reactive protein (CRP), procalcitonin, 
serum creatinine, lactate dehydrogenase (LDH), albumin, 
sodium, potassium, total calcium, bicarbonate concentra-
tions (Abbott Alinity instrument), leukocytes, lymphocytes, 
platelet counts, hemoglobin (Sysmex SE-9000 Hematology 
analyzer), and D-Dimer (Innovance D-Dimer kit on the Sie-
mens CS5100 automate).
A clear distinction between CKD and acute kidney injury 
(AKI) at admission was not always possible. Therefore, we 
used the term “decreased kidney function”, based on the 
CKD-Epidemiology equation and using an age-calibrated 
definition: estimated glomerular filtration rate (eGFR) below 
75, 60 or 45 mL/min/1.73 m2 for patients younger than 
40 years, between 40 and 65 years or older than 65 years, 
respectively [12, 13]. Because proteinuria and hematuria 
can be influenced by CKD status and/or AKI, analyses were 
repeated in subgroups without decreased eGFR at D0. AKI 
during hospitalization (i.e. after D0) was also considered, 
and based on the KDIGO definition, the first serum creati-
nine concentration at admission was considered the baseline 
[14]. Statistical analyses were repeated in subgroups with 
and without AKI during hospitalization.
Thorax CT-scanner staging was used to assess the radio-
graphic severity of COVID-19 pneumonia (percentage of 
the lungs involved) as reported by radiologists in medical 
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records (except for two patients): < 10%, between 10 and 
50%, and > 50%.
Severe cases on D0 were defined according to the guide-
lines of the Chinese National Health Commission: (1) res-
piratory rate > 30 breaths/min, (2) oxygen saturation < 93%, 
or (3)  PaO2/FiO2 ratio < 300 mmHg [2].
Mortality was checked for all patients in the medical 
records and/or confirmed by a phone call to the general 
practitioners until May 7th, 2020.
Statistical analyses
Data are expressed as mean ± standard deviation (SD) when 
the distribution was normal and as median with quartiles 
when not. Normality was assessed by the Shapiro–Wilk test. 
Comparison of two independent groups was performed 
using Mann–Whitney U test or Chi square test for continu-
ous and categorical variables, respectively. Kruskal–Wallis 
test with post hoc test according to Dunn and exact  Chi2 test 
(with Bonferroni correction) were performed to compare 
more than two groups for continuous variables and cate-
gorical variables, respectively. Univariate survival analysis 
(Kaplan–Meier) was done with categorical urine variables 
(according to KDIGO for proteinuria, to tertiles for urine 
α1-microglobulin and β2-microglobulin, and more than 10 
RBCs per field for hematuria) as strata. Cox proportional 
hazard regression modeling using the backward selection 
procedure was performed to study the risk of mortality asso-
ciated with all variables available in Table 1. Proteinuria, 
urine α1-microglobulin, hematuria, and the presence of UC 
were considered categorical variables. These urine variables 
were studied in non-adjusted models and in different models 
adjusted for other covariates at D0 that were significantly 
associated with mortality in the unadjusted model. All sta-




The  study cohort included 153 patients (flowchart of 
patient inclusion in Figure S1). The median time period 
between admission and D0 was 3 [2, 5] days. The patients 
excluded from the analysis because of the lack of urine 
samples (n = 72) were more frequently women and had a 
higher and earlier mortality rate (Table S1). The median 
age of our cohort was 70 [58-81] years, and 39% were 
women (Table 1). COVID-19 patients were character-
ized by high serum CRP and LDH concentrations and 
low lymphocyte number (Table  1). Eighty-two   % of 
patients were staged as with severe pneumonia. After 
D0, 29 patients (19%) developed AKI (7 reached stage 
2 and 5 reached stage 3). Twenty-three (15%) patients 
died during hospitalization and 4 deaths occurred after 
Table 1  Clinical and biological characteristics of the cohort at D0
Clinical








Women (n = 153) (%) 39
Weight (n = 130) (kg) 80 ± 17
Height (n = 125) (m) 1.70 [1.62;1.78]










Medical history (n = 153)
Hypertension (%)
Diabetes (%)








Intensive Care Unit (%) 22
Severe case (%) 82










C-reactive protein (n = 153) (mg/L)
C-reactive protein > 5 mg/L
81 [38;155]
97%






Lymphocytes (n = 151) (/mm3) 860 [655;1155]
Hemoglobin (n = 153) (g/dL) 12.3 [11.2;13.6]
Platelets (n = 153) (× 1000/mm3) 230 [165;301]
































 Journal of Nephrology
1 3
the patients left the hospital, leading to a mortality rate of 
18% during the study period. At the end of the follow-up, 
17 patients were still hospitalized.
Renal parameters
On D0, serum creatinine concentration was higher than 
normal in 27% of patients. A decreased renal function on 
D0 was observed in 24% of patients.
Proteinuria
The median proteinuria in our cohort was 455 [238;834] 
mg/g at D0. Fourteen percent (n = 21) of the patients had 
category 1 proteinuria, 42% (n = 64) had category 2 and 44% 
(n = 68) had category 3 proteinuria. Two patients had very 
high proteinuria (over 3500 mg/g). Clinical and biological 
characteristics according to proteinuria categories are shown 
in Table 2. Patients in higher proteinuria categories were 
older, and more severely affected (more patients in ICU and 
higher concentrations of CRP, as examples).
Table 2  Clinical and biological characteristics of the patients at D0 according to proteinuria staging at D0 (n = 153)
Ns not significant, eGFR estimated glomerular filtration rate
Dunn’s post hoc test p < 0.05: * proteinuria category 3, $ with proteinuria category 1
Chi2 test for categorical variables with Bonferroni correction: * with proteinuria category 3










(or exact  Chi2 test)
Clinical
Age (years) 61 [55;79] 66 [58;79] 75 [64;84] 0.02
Women (%) 43 42 34 ns
Weight (kg) 77 [65;92] 82 [69;95] 76 [67;91] ns
Height (m) 1.67 [1.61;1.77] 1.71 [1.63;1.78] 1.70 [1.65;1.79] ns



























Intensive Care Unit (%) 5* 17 31 0.006

































C-reactive protein (mg/L) 49 [13;74]* 78 [26;148]* 118 [61;169] 0.0002
Leukocyte count (/mm3) 5720 [4170;7170] 6005 [4735;10,025] 6605 [4875;9150] ns
Lymphocyte count (/mm3) 940 [763;1399] 910 [703;1248] 800 [543;1075] 0.04
Hemoglobin (g/dL) 13.2 [12.6;14.3]* 12.6 [11.1;13.8] 11.8 [11;13.1] 0.01
Platelets (x1,000/mm3) 248 [181;301] 240 [174;332] 201 [160;289] ns
Lactate Dehydrogenase (U/L) 254 [224;290]* 328 [258;408]$ 377 [285;555] 0.00005
D-Dimer (µg/L) 876 [371;1508] 952 [560;1609] 1202 [815;2945] 0.04
Albumin (g/L) 38 [33;41]* 35 [32;39]* 33 [33;41] 0.0002
Potassium (mmol/L) 4.16 [3.80;4.54] 4.12 [3.82;4.37] 4.04 [3.76;4.35] ns
Sodium (mmol/L) 141 [139;143] 141 [137;141] 139 [136;143] ns
Calcium (mmol/L) 2.23 [2.16;2.29]* 2.13 [2.05;2.23]* 2.03 [1.97;2.11] 0.000001
Bicarbonate (mmol/L) 26.3 [23.9;29.2] 24.7 [22.6;27.2] 25.7 [23.3;28.2] ns
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Among the 153 patients, a pre-admission value of pro-
teinuria was available for 51 patients, within a median 
preceding time of 383 [161;836] days. Among the 32 
patients with prior abnormal proteinuria, only 2 had nor-
mal proteinuria at D0. Conversely, among the 19 patients 
with prior normal proteinuria, only 4 remained within 
the normal range during the study period. One of the two 
patients with very high proteinuria during COVID-19 had 
normal proteinuria documented 57 days before D0. Limit-
ing analysis to the 112 patients with less than 10 RBCs per 
field, abnormal proteinuria was found in 81% of patients. 
Among the 114 patients without UC, 82% had proteinuria 
(38% with category 3). Among the 122 patients without 
decreased eGFR on D0, 83% had abnormal proteinuria 
(43% with category 3). Among the 124 patients who did 
not develop AKI after D0, 84% had abnormal proteinuria 
(38% with category 3).
The median urinary concentrations of α1-microglobulin 
and β2-microglobulin (n = 94) were 54 [27;122] mg/g and 
2.65 [0.40;14.15] mg/L, respectively. α1-microglobulin 
concentration was higher than 15 mg/g in 89% of patients. 
Urine β2-microglobulin was higher than 0.19 mg/L in 85% 
of patients. Among the 114 patients without UC, urine α1-
microglobulin over 15 mg/g and urine β2-microglobulin 
over 0.19 mg/L were found in 86% and 84% of the patients, 
respectively. Among the 122 patients without decreased 
eGFR on D0, 87% and 83% had α1-microglobulin and β2-
microglobulin concentrations over 15 mg/g and 0.19 mg/L, 
respectively. Among the 124 patients who did not develop 
AKI after D0, 87% and 82% had α1-microglobulin and 
Table 3  Clinical and biological characteristics of the patients at D0 according to tertiles of urinary α1-microglobulin at D0
Ns not significant, eGFR estimated glomerular filtration rate
Dunn’s post hoc test p < 0.05: * proteinuria category stage 3, $ with proteinuria category 1











(or exact  Chi2 test)
Clinical
Age (years) 66 [57;80]* 65 [58;73]* 77 [70;85] 0.005
Women (%) 49 34 33 ns
Weight (kg) 79 [65;94] 83 [69;93] 75 [68;90] ns
Height (m) 1.68 [1.61;1.79] 1.74 [1.67;1.79] 1.70 [1.65;1.76] ns



























Intensive Care Unit (%) 14 24 27 ns












C-reactive protein (mg/L) 61 [15;108] 135 [54;216]$ 95 [47;147]$ 0.0001
Leukocyte count (/mm3) 5940 [4260;5940] 6720 [5170;10,100] 6110 [4630;8615] ns
Lymphocyte count (/mm3) 925 [720;1350] 850 [630;1050] 820 [535;1095] ns
Hemoglobin (g/dL) 12.9 [12.0;14.0]* 12.6 [11.6;13.7]* 11.3 [10.5;13.0] 0.0004
Platelets (× 1000/mm3) 248 [179;331]* 247 [189;320]* 180 [140;252] 0.0007
Lactate Dehydrogenase (U/L) 288 [234;382] 372 [274;531]$ 361 [277;446]$ 0.007
D-Dimer (µg/L) 972 [564;1590] 1091 [789;3090] 1050 [776;2208] ns
Albumin (g/L) 37 [33;40] 33 [31;37]$ 33 [29;36]$ 0.0002
Potassium (mmol/L) 4.06 [3.76;4.40] 4.09 [3.91;4.30] 4.14 [3.72;4.48] ns
Sodium (mmol/L) 140 [138;143] 138 [136;140] 140 [137;143] 0.04
Calcium (mmol/L) 2.18 [2.10;2.29] 2.07 [2.00;2.16]$ 2.07 [1.97;2.12]$ 0.000004
Bicarbonate (mmol/L) 25.9 [23.2;27.5] 24.5 [22.5;26.7] 26.1 [23.6;28.9] ns
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β2-microglobulin concentrations over 15  mg/g and 
0.19 mg/L, respectively.
Table 3 describes the clinical and biological charac-
teristics of the patients according to tertiles of urine α1-
microglobulin and Table S2 describes the clinical and bio-
logical characteristics of the patients according to tertiles of 
urine β2-microglobulin. As for categories of total proteinu-
ria, higher tertiles of α1-microglobulin and β2-microglobulin 
are associated with older age and factors of severity.
Hematuria
The prevalence of hematuria in the 153-patient cohort was 
26%. In patients without UC (n = 114), the prevalence of 
hematuria was 13%.
Factors at D0 associated with mortality
Mortality was assessed for all patients on May 7th, 2020 
with a median follow-up of 27 [14, 30] days, D0 being the 
reference date. During the follow-up, 27 patients died (18%). 
The median time period between D0 and date of death was 
7 [4, 12] days.
Comparison of variables at D0 between patients who died 
versus survived is shown in Table S3. The patients who died 
were older, more frequently men and more frequently had 
a history of CKD and known active cancer. They had lower 
eGFR, lower platelet counts and higher CRP concentrations. 
For urine parameters, proteinuria, urine α1-microglobulin, 
urine β2-microglobulin, number of RBCs per field and UC 
were also significantly higher in deceased patients compared 
to surviving patients. Urine analyses were also performed in 
sub-groups and showed similar results (Table S4).
In the univariate Cox proportional hazards regression 
analysis, the following parameters were associated with 
mortality: age (HR 1.03 95% CI 1.00–1.06, p = 0.03), 
male gender (HR 2.94 95% CI 1.22–7.69, p = 0.02), his-
tory of CKD (HR 2.35 95% CI 1.03–5.38, p = 0.04), active 
cancer (HR 2.95 95% CI 1.19–7.34, p = 0.02), eGFR (for 
10 unit decrease: HR 1.16 95% CI 1.01–1.34, p = 0.03), 
CRP (for 10 unit increase: HR 1.04 95% CI 1.00–1.08, 
p = 0.04), platelet counts (for 10,000 unit decrease: HR 
1.01 95% CI 1.00–1.01, p = 0.004), category 3 proteinuria 
(versus category 2: HR 2.83 95% CI 1.19-6.72, p = 0.02), 
urine α1-microglobulin (tertiles 3 versus 1: HR 5.41 95% 
CI 1.83–16.00, p = 0.002 and tertiles 3 versus 2: HR 4.40 
95% CI 1.63-11.90, p = 0.004), hematuria (HR 2.82 95% 
Fig. 1  Survival curve according 
to proteinuria categorization (a), 
urine α1-microglobulin (b) or 
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CI 1.32–6.01, p = 0.007) and bladder catheterization (HR 
4.18 95% CI 1.95–8.95, p = 0.0002). Kaplan–Meier survival 
curves for proteinuria categories, urine α1-microglobulin 
tertiles and hematuria (RBCs more than 10 per field) as 
strata are shown in Fig. 1. High tertiles of proteinuria and 
urine α1-microglobulin and hematuria were associated with 
lower survival (logrank test, p = 0.008, 0.0001 and 0.005, 
respectively). Focusing on urine variables, multivariable 
Table 4  Association between 
urine variables (proteinuria, α1-
microglobulin, hematuria and 
urine catheter) and mortality 
in unadjusted and adjusted 
models in the whole cohort and 
subgroups
Only significant variables are shown in the table. + if the association is positive and − if the association is 
negative (or protective)
CRP C-reactive protein, eGFR estimated glomerular filtration rate, Ht hematuria, P proteinuria, Ns not sig-
nificant, Tα Tertile of urine α1-microglobulin, UC Urine catheter, Model 1 adjusted for age and gender, 
Model 2 Model 1 + adjusted for CKD history and active cancer, Model 3 Model 2 + adjusted for eGFR, 
CRP and platelet counts, Model 4 Model 3 + adjusted for hematuria and urinary catheter
Unadjusted Model 1 Model 2 Model 3 Model 4
The whole cohort
N = 153











































Cohort with normal eGFR at D0
N = 122

































Cohort without urinary catheter
N = 114













Hematuria Ns Age+ Age+ CRP+
 Journal of Nephrology
1 3
Cox adjusted analyses are shown in Table 4: category of 
proteinuria was not associated with mortality in the adjusted 
models, whereas urine α1-microglobulin remained associ-
ated with mortality in the adjusted models, except when the 
variable UC was included. Hematuria was associated with 
mortality in the adjusted models. However, such association 
was not observed in the subgroup of patients without UC. 
The presence of UC was highly predictive of mortality in all 
models. In patients with normal eGFR on D0, proteinuria 
and urine α1-microglobulin were still associated with mor-
tality in the fully-adjusted model. The same results were 
observed in the sub-group without UC at D0. Forcing vari-
ables like score severity and hospitalization in ICU at D0 in 
the Cox models did not modify the results. 
Follow‑up results at day 7
Among the 153 patients, 76 left the hospital less than 
7 days after D0. Among the 77 patients still hospitalized at 
D7, 48 had a second measurement of proteinuria. Among 
them, the median concentration of proteinuria and urine 
α1-microglobulin at D0 was 493 [307;929] mg/g and 76 
[37;144] mg/g, and 280 [170;521] mg/g and 60 [34;125] 
mg/g at D7, respectively. The median decrease in pro-
teinuria and α1-microglobulin concentration was − 178 
[− 531;− 52] mg/g (relative decrease of 43%) and − 17 
[− 56;32] mg/g (relative decrease of 21%), respectively. 
Excluding the patients who died during the study period 
(n = 8) and those who were still hospitalized on May 7th 
(n = 6), it leaves 34 patients who left the hospital alive with 
a median concentration of proteinuria and α1-microglobulin 
on D0 of 483 [302;1062] mg/g and 60 [33;138] mg/g, 
and of 203 [109;328] mg/g and 34 [14;84] mg/g on D7, 
respectively. The median decrease in proteinuria and α1-
microglobulin concentration was − 256 [− 717;− 98] mg/g 
(relative decrease of 58%) and − 20 [− 91;− 3] mg/g (rela-
tive decrease of 43%), respectively. Among these patients, 
proteinuria categories 1, 2 and 3 were observed in 9%, 44% 
and 47% respectively on D0. The prevalence was 32%, 50% 
and 18%, respectively on D7. Among the 3 patients with cat-
egory 1 on D0, 2 progressed to category 2 at D7. Among the 
15 patients with category 2 on D0, 8 decreased to category 
1, one progressed to category 3 and 6 remained at category 
2 proteinuria on D7. Among the 16 patients with category 3 
proteinuria on D0, 2 decreased to category 1, 9 to category 
2 and 5 remained at category 3 on day 7.
Discussion
In a retrospective analysis of a cohort of 153 hospital-
ized patients with COVID-19, we found a high prevalence 
(close to 80%) of abnormal proteinuria (including 43% of 
them with category 3 proteinuria). Characterization of the 
proteinuria showed a predominant pattern of tubular pro-
teinuria, as depicted by concomitant high levels of urine 
α1-microglobulin and β2-microglobulin. Eighty-nine  % of 
patients had increased α1-microglobulin values. Interest-
ingly, total proteinuria and α1-microglobulin concentrations 
were predictive of mortality in our cohort.
The high prevalence of proteinuria in patients with 
COVID-19 was not related to hematuria in our study. Indeed, 
excluding patients with hematuria (26%), abnormal protein-
uria was still found in 81% of cases. Moreover, proteinuria 
was also observed in patients who did not develop AKI after 
D0. Whether proteinuria is directly caused by SARS-CoV-2 
infection of the renal parenchyma cannot be proven, due to 
the design of our study. However, pre-admission values of 
proteinuria were available for 51 patients and only 4 out 
of 19 patients who had prior normal proteinuria also had 
normal values at D0. This suggests de novo proteinuria 
due to COVID-19. Cheng et al. [2] observed proteinuria in 
43.9% of COVID-19 patients. The same group in another 
publication reported that proteinuria was present in 65.8% 
of 333 hospitalized patients [15]. Hirsch et al. [16] found a 
prevalence of 42.1%, by dipstick results, in 646 patients in 
New-York City.
The present study is one of the first studies that char-
acterize and quantify proteinuria in patients hospitalized 
with COVID-19. The fact that we measured proteinuria 
instead of employing dipsticks may per se explain the higher 
prevalence of proteinuria in our cohort, especially because 
dipstick testing is more sensitive for albuminuria than for 
tubular proteinuria [7]. Our analysis further revealed that 
proteinuria is mainly of tubular origin. The underlying 
mechanisms remain unknown. The design of the current 
study did not allow us to formally distinguish acute tubu-
lar necrosis (ATN) caused by a septic condition before D0 
or admission to hospital, or low-oxygen delivery to tissues 
from specific cytopathic lesions caused by SARS-CoV-2 
itself [17]. Some preliminary results with kidney biopsies 
(including electronic microscopy) suggest direct virus-medi-
ated tubular injury [18–20]. This hypothesis is reinforced by 
the preferential tubular expression of angiotensin convert-
ing enzyme 2 which is suspected to participate in cellular 
entry of the SARS-CoV-2 [4, 21, 22]. However, the presence 
of the virus in the kidney (and in urine) is still the sub-
ject of active debate and further studies are needed [18–20, 
22–24]. In our study, it is interesting to note that there were 
far more patients with isolated proteinuria than patients with 
decreased eGFR at admission (20% at D0). Only a small 
number of patients were hospitalized in intensive care units 
at D0, and the occurrence of AKI after D0 was19%.
Fifteen percent of patients died during hospitalization, 
a prevalence comparable to data available in New York 
City [25], Northern Italy [26], and China [2]. Parameters 
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at D0 associated with mortality in our cohort (age, sex, 
history of CKD, active cancer, lower eGFR and platelet 
counts, and higher CRP) have already been reported by 
others [27, 28]. Interestingly, proteinuria and even more 
so, uriary α1-microglobulin, seem to be associated with 
mortality. Urine catheterization was highly predictive of 
mortality, probably as a reflection of frailty of the patient 
and/or severity of the disease. Because urine catheteri-
zation itself can cause hematuria and thus contribute to 
“false” total proteinuria, it is legitimate to discard patients 
with UC at D0 from the survival analysis. In the sub-group 
without UC, the predictive value of proteinuria and urine 
α1-microglobulin was confirmed. Hematuria was not pre-
dictive of mortality per se. Cheng et al. [2] also found an 
association between kidney involvement, including pro-
teinuria (by dipstick), and in-hospital death. Once again, 
the design of our study only allows to generate hypoth-
eses to explain the higher mortality rate in patients with 
abnormal proteinuria (higher viral load and early multiple 
organ involvement [17, 29] or marker of ATN and/or AKI). 
Association is not causation, and the main cause of death 
in COVID-19 was respiratory failure, not kidney injury. In 
this context, and whatever the potential mechanisms, asso-
ciation between tubular proteinuria and mortality should 
be interpreted with caution. Residual confounding factors 
in the multivariable analysis remain possible.
The long-term renal consequences of COVID-19 are 
still unknown and will require follow-up studies. Pei et al. 
[15] observed that proteinuria often resolved (in 68.5% of 
the patients with prior proteinuria) within 3 weeks. Our 
preliminary data seem reassuring, but more distant follow-
up of proteinuria is needed.
Our study has limitations. First, the study is single-
center and retrospective. Second, all analyses were per-
formed on D0, which was defined by the time of urine 
analysis. A median period of 3 days separates admission 
and D0, and our results must be interpreted accordingly. 
Significant differences between included and non-included 
patients (Table S1) are observed, essentially in terms of 
mortality and time to death. This bias is mainly due to a 
lack of urine collection in severely ill patients who died 
rapidly after admission. The analyses concerning mortality 
rate should also be considered with caution because of the 
small sample size. Tubular involvement suggested in our 
study does not exclude exceptional forms of glomerular 
involvement like collapsing glomerulopathy [30]. Data 
about urinary albumin were not available (not reimbursed 
by the Belgian health system) and mixed proteinuria can-
not be excluded. Lastly, important variables like weight 
and height were not available for some patients.
In conclusion, a very high rate of tubular proteinuria is 
found in hospitalized COVID-19 patients. Abnormal pro-
teinuria and/or elevated urine α1-microglobulin excretion 
were associated with mortality, in adjusted models. This 
is especially relevant in patients with normal eGFR at D0 
and in patients without urinary catheters.
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